戴纳基启动Z-Rostudirsen治疗杜氏肌营养不良症的三期Forzetto试验,为美国加速批准计划的生物制剂许可申请提交铺路

美股速递
May 20

戴纳基宣布,已启动其在研药物Z-Rostudirsen用于治疗杜氏肌营养不良症(DMD)的三期Forzetto临床试验。此举旨在为计划向美国监管机构提交的加速批准生物制剂许可申请提供支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10